

12-05-01

10/24/01
1129 U.S. PTO

11000 U.S. PTO
10/001755
10/24/01

Docket Number 4-20251/C/MA 2102/PCT/CONT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 751039486 US
Express Mail Label Number

October 24, 2001
Date of Deposit

Address to: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b)(1) is a **continuation** of prior Application No. 09/257,446, which is a 371 of PCT/GB95/02821, filed April 12, 1995.

Applicant (or identifier): TAYLOR ET AL.

Title: LIPOSOMAL INTERFERON HYBRID COMPOSITION

Enclosed are:

1. ☒ Specification (Including Claims and Abstract) - 9 pages
2. ☐ Drawings - sheets
3. Declaration and Power of Attorney
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (signed or with indication that original was signed)
 - i. ☐ Deletion of Inventors
Signed statement attached deleting inventor(s) named in the prior application
4. ☒ Incorporation By Reference
The entire disclosure of the prior application, from which a copy of the Declaration and Power of Attorney is supplied under Box 3b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
5. ☐ Microfiche Computer Program (appendix)
6. Nucleotide and/or Amino Acid Sequence Submission
 - ☐ Computer Readable Copy
 - ☐ Paper Copy
 - ☐ Statement Verifying Identity of Above Copies
7. ☒ Preliminary Amendment
8. ☐ Assignment Papers (Cover Sheet & Document(s))
9. ☐ English Translation of
10. ☐ Information Disclosure Statement
11. ☐ Certified Copy of Priority Document(s)
12. ☒ Return Receipt Postcard
13. ☒ Other: Copy of Extension of Time (3 month)

10001755-102401

- ☒ The right to elect an invention or species that is different from that elected in parent Application No. 09/257,446 in the event of a restriction or election of species requirement that is identical or substantially similar to that made in said parent application is hereby reserved.

Filing fee calculation:

- ☒ Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
☒ Before calculating the filing fee, please cancel claims 1-21.

Basic Filing Fee							\$	740
Multiple Dependent Claim Fee (\$ 280)							\$	
Foreign Language Surcharge (\$ 900)							\$	
	For	Number Filed		Number Extra		Rate		
Extra Claims	Total Claims	13	-20	0	x	\$ 18	=	\$
	Independent Claims	1	-3	0	x	\$ 84	=	\$
TOTAL FILING FEE							\$	740

- ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$740. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.


Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie
 Novartis Corporation
 Patent and Trademark Dept.
 564 Morris Avenue
 Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (908) 522-6955.

Respectfully submitted,

Date: October 24, 2001


 John D. Thallemer
 Attorney for Applicants
 Reg. No. 34,940
 Tel. No. (908) 522-6950

1000155-10401
 10401-5520001

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EC 8200 14650 US
Express Mail Label Number

October 24, 2001
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1642

TAYLOR ET AL.

Examiner: G. Bansal

APPLICATION NO: 09/257,446

FILED: FEBRUARY 25, 1999

FOR: LIPOSOMAL INTERFERON HYBRID COMPOSITION

Assistant Commissioner for Patents
Washington, D.C. 20231

APPEAL BRIEF
PETITION FOR EXTENSION OF TIME

Sir:

The period for filing a Brief on Appeal has a shortened statutory time set to expire on July 24, 2001. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$920 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Date: October 24, 2001


John D. Thallemer
Attorney for Applicants
Reg. No. 34,940
Phone No. (908) 522-6950

1000 U.S. PRO
10/001755
10/24/01